Igc Pharma Inc (IGC) Stock Price, Quote & News

Company Profile

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MI...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 983 0998

Website: igcpharma.com

Address:

10224 Falls Road, Potomac, United States

GordoHLYK13 Aug. 22 at 12:18 PM

$IGC is starting to heat up 🔥 Friday’s +8.23% move wasn’t just cannabis-sector beta. Phase 2 CALMA is nearing full enrollment, Q4 2026 topline data is coming, and insiders converted ~$1.15M of debt into shares at $0.27. With the binary catalyst getting closer and momentum building, don’t underestimate IGC—this setup could get very interesting. 🚀 $INCR $RYM $TRVL

0 · Reply

Shawshank_book_keeper Aug. 22 at 8:46 AM

$IGC

0 · Reply

RocketQueen Aug. 22 at 4:57 AM

$IGC we'll be in the .40s soon.

0 · Reply

SaySomethingNice Aug. 22 at 2:44 AM

$IGC bye-bye .20-.30 forever soon..

0 · Reply

NewsAndFilings Aug. 21 at 10:06 PM

MicroCaps $IGC, $BIVI, $QTEX, $ORBS, $RIME: Sub-$1 Stocks to Watch Now https://thestreetreports.com/microcaps-igc-bivi-qtex-orbs-rime-sub-1-stocks-to-watch-now/

0 · Reply

Shawshank_book_keeper Aug. 21 at 9:23 PM

$IGC keep climbing next week

0 · Reply

SaySomethingNice Aug. 21 at 8:42 PM

$IGC hidden gem 2026..

0 · Reply

RocketQueen Aug. 21 at 7:53 PM

$IGC closing into strength is a positive sign.

0 · Reply

RocketQueen Aug. 21 at 7:06 PM

$IGC this stock is so underpriced and undervalued. Volume is picking up.

0 · Reply

OffComesTheShirt Aug. 21 at 6:31 PM

$IGC 11% Off Comes The Shirt

1 · Reply

IGC Pharma reports Q2 EPS (3c) vs. (2c) last year

2026-08-17T12:45:25.000Z - 5 days ago

IGC Pharma sees cash runway for 12 months from quarterly report filing date

Aug 17, 2026, 8:30 AM EDT - 5 days ago

IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure

Aug 14, 2026, 7:00 AM EDT - 8 days ago

IGC Pharma Quarterly report: Q2 2026

2026-08-11T12:46:11.000Z - 11 days ago

IGC Pharma strengthens regulatory readiness of Phase 2 CALMA trial

Aug 11, 2026, 8:30 AM EDT - 11 days ago

IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout

2026-07-29T12:40:22.000Z - 24 days ago

IGC Pharma evaluates potential civil remedies following federal jury verdict

Jul 29, 2026, 8:30 AM EDT - 24 days ago

IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign

Jul 13, 2026, 7:00 AM EDT - 5 weeks ago

IGC Pharma Slides: Investor presentation

Jul 9, 2026, 9:00 AM EDT - 6 weeks ago

IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow

2026-07-07T13:26:29.000Z - 6 weeks ago

IGC Pharma CEO, principal financial officer purchase over $1.15M of stock

Jul 7, 2026, 9:00 AM EDT - 6 weeks ago

IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company

2026-06-23T16:59:03.000Z - 2 months ago

IGC Pharma announced beta version of Agentic Harmonization Assistant

Jun 23, 2026, 8:30 AM EDT - 2 months ago

IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow

2026-06-11T12:43:47.000Z - 2 months ago

IGC Pharma reaches 146-patient enrollment target for Phase 2 Calma trial

Jun 11, 2026, 8:30 AM EDT - 2 months ago

IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis

Jun 9, 2026, 8:30 AM EDT - 2 months ago

Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts

2026-06-02T15:20:34.000Z - 2 months ago

IGC Pharma adds Mount Sinai clinical site as CALMA trial advances

Jun 2, 2026, 8:30 AM EDT - 2 months ago

IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis

May 19, 2026, 5:30 PM EDT - 3 months ago

IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment

2026-05-15T13:00:12.000Z - 3 months ago

IGC Pharma to present new Tau-PET biomarker research at Global Tau conference

May 15, 2026, 8:00 AM EDT - 3 months ago

IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference

May 15, 2026, 8:00 AM EDT - 3 months ago

IGC Pharma Quarterly report: Q1 2026

Apr 28, 2026, 12:15 PM EDT - 4 months ago

IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase

2026-04-22T13:29:55.000Z - 4 months ago

IGC adds Kerwin Medical Center as clinical site for Phase 2 CALMA trial

Apr 22, 2026, 8:30 AM EDT - 4 months ago

IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion

2026-04-20T14:17:51.000Z - 4 months ago

IGC Pharma secures Colombian authorization for psilocybin research

Apr 20, 2026, 8:30 AM EDT - 4 months ago

IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia

2026-04-14T12:36:26.000Z - 4 months ago

IGC Pharma reaches 80% enrollment in Phase 2 CALMA trial

Apr 14, 2026, 8:30 AM EDT - 4 months ago

IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout

Apr 8, 2026, 12:45 PM EDT - 4 months ago

Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts

2026-04-07T12:50:45.000Z - 4 months ago

IGC announces activation of new clinical trial sate for Phase 2 CALMA trial

Apr 7, 2026, 8:00 AM EDT - 4 months ago

IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease

2026-03-30T12:38:30.000Z - 5 months ago

IGC Pharma enters national media partnership with New to The Street

Mar 30, 2026, 8:00 AM EDT - 5 months ago

IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness

2026-03-25T12:20:15.000Z - 5 months ago

IGC Pharma, New to The Street launch 12-part national media partnership

Mar 19, 2026, 9:00 AM EDT - 5 months ago

IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025

Mar 18, 2026, 9:00 AM EDT - 5 months ago

IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026

Feb 26, 2026, 8:30 AM EST - 6 months ago

IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research

Feb 24, 2026, 8:30 AM EST - 6 months ago

IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets

Feb 23, 2026, 8:30 AM EST - 6 months ago

IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial

Feb 18, 2026, 1:00 PM EST - 6 months ago

IGC Pharma Transcript: Status update

Feb 17, 2026, 8:30 AM EST - 6 months ago

IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances

Feb 12, 2026, 8:30 AM EST - 6 months ago

IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets

Feb 10, 2026, 8:30 AM EST - 6 months ago

IGC Pharma Announces Equity Research Update by Alliance Global Partners

Feb 9, 2026, 8:30 AM EST - 6 months ago

IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center

Feb 2, 2026, 8:30 AM EST - 7 months ago

IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation

Jan 22, 2026, 9:00 AM EST - 7 months ago

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York

Jan 12, 2026, 9:00 AM EST - 7 months ago

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia

Jan 6, 2026, 8:00 AM EST - 8 months ago

IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability

Jan 5, 2026, 9:00 AM EST - 8 months ago

IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial

Dec 19, 2025, 9:00 AM EST - 8 months ago

IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum

Dec 15, 2025, 9:00 AM EST - 8 months ago

IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines

Dec 10, 2025, 9:00 AM EST - 9 months ago

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock.

Dec 9, 2025, 9:00 AM EST - 9 months ago

IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

Dec 3, 2025, 7:00 AM EST - 9 months ago

IGC Pharma Registration statement: Registration Filing

Dec 2, 2025, 9:00 AM EST - 9 months ago

IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease

Nov 25, 2025, 9:00 AM EST - 9 months ago

IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends

Nov 17, 2025, 11:00 AM EST - 9 months ago

IGC Pharma Earnings Call Transcript: Q3 2025

Nov 17, 2025, 11:00 AM EST - 9 months ago

IGC Pharma Quarterly report: Q3 2025

Nov 17, 2025, 8:30 AM EST - 9 months ago

IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital

Nov 17, 2025, 7:00 AM EST - 9 months ago

IGC Pharma Registration statement: Registration Filing

Nov 13, 2025, 9:00 AM EST - 10 months ago

USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders

Nov 10, 2025, 9:00 AM EST - 10 months ago

IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025

Nov 3, 2025, 8:52 AM EST - 10 months ago

IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline

Oct 22, 2025, 9:00 AM EDT - 10 months ago

IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"

Oct 14, 2025, 9:00 AM EDT - 11 months ago

IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences

Oct 10, 2025, 7:50 PM EDT - 11 months ago

IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders

Oct 7, 2025, 9:00 AM EDT - 11 months ago

IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease

Sep 29, 2025, 9:00 AM EDT - 11 months ago

IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial

Sep 24, 2025, 9:00 AM EDT - 11 months ago

IGC Pharma Announces Preclinical Data Demonstrating TGR-63's Dual Action on Alzheimer's Pathology

Sep 22, 2025, 9:00 AM EDT - 11 months ago

IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

Sep 9, 2025, 9:00 AM EDT - 1 year ago

IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection

GordoHLYK13 Aug. 22 at 12:18 PM

0 · Reply

Shawshank_book_keeper Aug. 22 at 8:46 AM

$IGC

0 · Reply

RocketQueen Aug. 22 at 4:57 AM

$IGC we'll be in the .40s soon.

0 · Reply

SaySomethingNice Aug. 22 at 2:44 AM

$IGC bye-bye .20-.30 forever soon..

0 · Reply

NewsAndFilings Aug. 21 at 10:06 PM

MicroCaps $IGC, $BIVI, $QTEX, $ORBS, $RIME: Sub-$1 Stocks to Watch Now https://thestreetreports.com/microcaps-igc-bivi-qtex-orbs-rime-sub-1-stocks-to-watch-now/

0 · Reply

Shawshank_book_keeper Aug. 21 at 9:23 PM

$IGC keep climbing next week

0 · Reply

SaySomethingNice Aug. 21 at 8:42 PM

$IGC hidden gem 2026..

0 · Reply

RocketQueen Aug. 21 at 7:53 PM

$IGC closing into strength is a positive sign.

0 · Reply

RocketQueen Aug. 21 at 7:06 PM

$IGC this stock is so underpriced and undervalued. Volume is picking up.

0 · Reply

OffComesTheShirt Aug. 21 at 6:31 PM

$IGC 11% Off Comes The Shirt

1 · Reply

MrTicker Aug. 21 at 6:30 PM

$IGC a close above .30 would be a good way to end the week. We could see a slow upward trend with new base forming in anticipation of positive results. Buying and holding at this level.

1 · Reply

SaySomethingNice Aug. 21 at 6:26 PM

$IGC she's got EYES on her now..

0 · Reply

SaySomethingNice Aug. 21 at 5:49 PM

$IGC Book it...

1 · Reply

GordoHLYK13 Aug. 21 at 5:16 PM

$ABBV $IGC $NVDA

0 · Reply

Shawshank_book_keeper Aug. 21 at 5:08 PM

$IGC

0 · Reply

_jaydub_ Aug. 21 at 4:47 PM

$IGC Did everyone just see that? Massive loading!

0 · Reply

_jaydub_ Aug. 21 at 4:46 PM

$IGC MM Circle jerk!

0 · Reply

SaySomethingNice Aug. 21 at 4:35 PM

$IGC eyes getting on here..

0 · Reply

_jaydub_ Aug. 21 at 3:36 PM

$IGC Volume is ticking up

0 · Reply

GordoHLYK13 Aug. 21 at 1:19 PM

$IGC reminder ladies and gentlemen Phase 2 doesn’t need to be perfect—it just needs to beat the placebo with statistically meaningful efficacy while maintaining a solid safety profile. If CALMA delivers, $IGC could get serious attention from Big Pharma. 🚀 $ABBV $NVDA

0 · Reply

GordoHLYK13 Aug. 21 at 1:11 PM

$IGC is already in Phase 2 CALMA—this isn’t a preclinical story. If the Phase 2 topline confirms the encouraging interim efficacy and safety signals, IGC could go from overlooked micro-cap to a serious Big Pharma target for partnership, licensing, or acquisition discussions. 🚀 Phase 2 success changes the game. Big Pharma doesn’t chase potential—it chases validated clinical data. If CALMA delivers, don’t be surprised when the big boys start chasing $MRNA $LLY $JNJ

0 · Reply

GordoHLYK13 Aug. 21 at 12:15 PM

$IGC Price: ~$0.28–$0.29 Main Catalyst: Phase 2 CALMA trial readout (IGC-AD1 for Alzheimer's agitation) expected in Q4 2026. Analyst Target: Consensus target around $5.50 (1,000%+ speculative upside if Phase 2 succeeds). Short Setup: Low total short interest (~0.54M shares / ~0.6% of float), meaning market movement will be driven strictly by clinical trial news and volume rather than a short squeeze. https://igcpharma.com/

0 · Reply

Market Cap	28.66M
Revenue (ttm)	1.27M
Net Income (ttm)	-7.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.15

Volume	1,867,400
Avg Vol	630,462
Day's Range	N/A - N/A
Shares Out	103.38M
Stochastic %K	95%
Beta	0.45
Analysts	Sell
Price Target	$4.25